KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Charles River Laboratories International (CRL) Non-Current Deferred Tax Liability (2016 - 2025)

Historic Non-Current Deferred Tax Liability for Charles River Laboratories International (CRL) over the last 14 years, with Q3 2025 value amounting to $123.0 million.

  • Charles River Laboratories International's Non-Current Deferred Tax Liability fell 2667.07% to $123.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $123.0 million, marking a year-over-year decrease of 2667.07%. This contributed to the annual value of $107.0 million for FY2024, which is 7576.7% down from last year.
  • Per Charles River Laboratories International's latest filing, its Non-Current Deferred Tax Liability stood at $123.0 million for Q3 2025, which was down 2667.07% from $109.3 million recorded in Q2 2025.
  • Charles River Laboratories International's 5-year Non-Current Deferred Tax Liability high stood at $441.4 million for Q4 2023, and its period low was $107.0 million during Q4 2024.
  • Its 5-year average for Non-Current Deferred Tax Liability is $223.4 million, with a median of $207.0 million in 2021.
  • As far as peak fluctuations go, Charles River Laboratories International's Non-Current Deferred Tax Liability surged by 3011.52% in 2021, and later crashed by 7576.7% in 2024.
  • Charles River Laboratories International's Non-Current Deferred Tax Liability (Quarter) stood at $420.6 million in 2021, then increased by 2.97% to $433.1 million in 2022, then rose by 1.92% to $441.4 million in 2023, then plummeted by 75.77% to $107.0 million in 2024, then increased by 15.0% to $123.0 million in 2025.
  • Its last three reported values are $123.0 million in Q3 2025, $109.3 million for Q2 2025, and $107.3 million during Q1 2025.